Clinical context An adult with B-cell precursor acute lymphoblastic leukemia develops fever, hypotension, hypoxemia, confusion, word-finding difficulty, and tremor 18 hours after a continuous blinatumomab infusion begins, raising concern for concurrent cytokine release syndrome and neurologic toxicity. Place the actions in the safest sequence.
Ordered Response
Choose your responses, then check the answer.
Explanation
The sequence stops the causal exposure, stabilizes vital functions, evaluates overlapping causes, delivers authorized syndrome-directed treatment, and verifies a durable response before any treatment decision.
Quick answer Sequence interrupt, stabilize, investigate, treat, and reassess.
Why this is correct Laboratory evaluation and infection workup proceed rapidly but never delay support for shock, hypoxemia, seizure, or declining consciousness.
Easy analogy or mental picture Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.
Memory hook Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.
NCLEX decision rule Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.
Why the other choices are wrong Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.
References
1DailyMed: BLINCYTO (blinatumomab)Cytokine release syndrome, neurologic toxicity including ICANS, interruption, corticosteroid treatment, and monitoring
Clinical contextAn adult with B-cell precursor acute lymphoblastic leukemia develops fever, hypotension, hypoxemia, confusion, word-finding difficulty, and tremor 18 hours after a continuous blinatumomab infusion begins, raising concern for concurrent cytokine release syndrome and neurologic toxicity.